Monitoring the AML1/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia

Pediatric Blood and Cancer

Volumn 61, Issue 10, 2014, Pages 1761-1766

  Zhang, Li ^a   Cao, Zeng ^a   Ruan, Min ^a   Zeng, Qiang ^b   Zhao, Liang ^b   Li, Qinghua ^a   Zou, Yao ^a   Wang, Jianxiang ^a   Zhu, Xiaofan ^a  

^a INSTITUTE OF HEMATOLOGY AND BLOOD DISEASES HOSPITAL   (China)

^b TIANJIN CENTERS FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Acute; AML1 ETO; Child; Leukemia; Myeloid; Polymerase chain reaction

Indexed keywords

CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; AML1 ETO FUSION GENE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG MEGADOSE; FEMALE; FOLLOW UP; FUSION GENE; HUMAN; HUMAN TISSUE; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACUTE; AML1/ETO; CHILD; LEUKEMIA; MYELOID; POLYMERASE CHAIN REACTION;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM, RESIDUAL; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; ROC CURVE; TRANSCRIPTION, GENETIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84908509130     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.25109     Document Type: Article

References (26)

1. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol 2010; 28:2674-2681.
2. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol 2010; 28:2682-2689.
3. Raimondi SC, Chang MN, Ravindranath Y, et al. Chromosomal abnormalities in 478 children with acute myeloid leukemia: Clinical characteristics and treatment outcome in a cooperative pediatric oncology group study-POG 882. Blood 1999; 94:3707-3716.
4. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol 1999; 17:3767-3775.
5. Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 2005; 23:5705-5717.
6. Satake N, Maseki N, Kozu T, et al. Disappearance of AML1-MTG8(ETO) fusion transcript in acute myeloid leukaemia patients with t(8;21) in long-term remission. Br J Haematol 1995; 91:892-898.
7. Jurlander J, Caligiuri MA, Ruutu T, et al. Persistence of the AML1/ETO fusion transcript in patients treated with allogeneic bone marrow transplantation for t(8;21) leukemia. Blood 1996; 88:2183-2191.
8. Miyamoto T, Nagafuji K, Akashi K, et al. Persistence of multipotent progenitors expressing AML1/ETO transcripts in long-term remission patients with t(8;21) acute myelogenous leukemia. Blood 1996; 87:4789-4796.
9. Yin JA, O'Brien MA, Hills RK, et al. Minimal residual disease monitoring by quantitative RT-PCR in core binding factor AML allows risk stratification and predicts relapse: Results of the United Kingdom MRC AML-15 trial. Blood 2012; 120:2826-2835.
10. Lane S, Saal R, Mollee P, et al. A > or =1 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma 2008; 49:517-523.
11. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood 2013; 121:2213-2223.
12. Wattjes MP, Krauter J, Nagel S, et al. Comparison of nested competitive RT-PCR and real-time RT-PCR for the detection and quantification of AML1/MTG8 fusion transcripts in t(8;21) positive acute myelogenous leukemia. Leukemia 2000; 14:329-335.
13. Viehmann S, Teigler-Schlegel A, Bruch J, et al. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia 2003; 17:1130-1136.
14. Kondo M, Kudo K, Kimura H, et al. Real-time quantitative reverse transcription-polymerase chain reaction for the detection of AML1-MTG8 fusion transcripts in t(8;21)-positive acute myelogenous leukemia. Leuk Res 2000; 24:951-956.
15. Tsukimoto I, Tawa A, Horibe K, et al. Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: The AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2009; 27:4007-4013.
16. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987; 162:156-159.
17. Van Dongen JJM, Macintyre EA, Gabert JA, et al. Standardized RT-PCR analysis of fusion gene transcripts from chromosome aberrations in acute leukemia for detection of minimal residual disease. Report of the BIOMED-1 Concerted Action: Investigation of minimal residual disease in acute leukemia. Leukemia 1999; 13:1901-1928.
18. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of "realtime" quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia: A Europe Against Cancer program. Leukemia 2003; 17:2318-2357.
19. Beillard E, Pallisgaard N, van der Velden VH, et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using "real-time" quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR). A Europe Against Cancer Program. Leukemia 2003; 17:2474-2486.
20. Arellano M, Bernal-Mizrachi L, Pan L, et al. Prognostic significance of leukopenia at the time of diagnosis in acute myeloid leukemia. Clin Lymphoma Myeloma Leuk 2011; 11:427-432.
21. Mallett S, Timmer A, Sauerbrei W, et al. Reporting of prognostic studies of tumour markers: A review of published articles in relation to REMARK guidelines. Br J Cancer 2010; 102:173-180.
22. Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 2005; 19:367-372.
23. Hoyos M, Nomdedeu JF, Esteve J, et al. Core binding factor acute myeloid leukemia: The impact of age, leukocyte count, molecular findings, and minimal residual disease. Eur J Haematol 2013; 91:209-218.
24. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood 2010; 115:2372-2379.
25. Miyamoto T, Weissman IL, Akashi K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. Proc Natl Acad Sci USA 2000; 97:7521-7526.
26. Zhang L, Li Q, Li W, et al. Monitoring of minimal residual disease in acute myeloid leukemia with t(8;21)(q22;q22). Int J Hematol 2013; 97:786-792.